Related Experiment Videos
[Intra-aortic balloon counterpulsation as percutaneous therapy option in cardiogenic shock]
G Bauriedel1, M Schwaiblmair, E Kreuzer
1Medizinische Klinik I, Klinikum Grosshadern, Universität München.
Insights
This case study highlights intra-aortic balloon pump (IABP) use for myocardial infarction with cardiogenic shock. IABP, combined with revascularization, proved highly effective in stabilizing a critically ill patient.
Area of Science:
- Cardiology
- Interventional Cardiology
Background:
- Recurrent myocardial infarction (MI) can lead to cardiogenic shock.
- Early revascularization and medical management are crucial but may be insufficient in severe cases.
Observation:
- A 40-year-old male experienced anterior wall re-infarction with cardiogenic shock post-thrombolysis for posterior MI.
- Despite high-dose catecholamines and coronary angioplasty, hemodynamic instability persisted.
Findings:
- Percutaneous intra-aortic balloon counterpulsation (IABP) was initiated, leading to hemodynamic improvement.
- IABP allowed for significant reduction in catecholamine support and mechanical ventilation settings.
- The IABP catheter was removed after 5 days without complication, with sustained cardiac function improvement.
Implications:
- Intra-aortic balloon pump counterpulsation is a vital treatment for myocardial infarction complicated by cardiogenic shock.
- Combining IABP with interventional revascularization offers a potent strategy for managing refractory cardiogenic shock.
- This case underscores the role of mechanical circulatory support in improving outcomes for high-risk MI patients.
Abstract:
Six months after sustaining a posterior wall myocardial infarction a 40-year-old man had a further infarction in the anterior wall region. After thrombolysis treatment with recombinant tissue plasminogen activator the patient was at first symptom-free and haemodynamically stable, but 48 hours later another anterior wall re-infarction occurred with cardiogenic shock. Despite infusions of catecholamines at highest dosage and successful coronary angioplasty the circulation became critically unstable and percutaneously introduced intraaortic balloon counterpulsation (IABCP) was commenced. As the haemodynamics improved catecholamine dosage was markedly reduced and then discontinued over the subsequent 24-48 hours and inspiratory oxygen concentration of the ventilated patient was decreased from 100% to 40%. After a total of 5 days the IABCP catheter was removed without complication. The cardiac pump action showed further improvement in the following days. 6 months later the patient's condition was stable in grade II-III (New York Heart Association classification) heart failure. This case illustrates the place of IABPC as a highly effective treatment option in myocardial infarction with cardiogenic shock, especially when combined with interventional revascularisation procedures.